Stockreport

atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

ATAI Life Sciences N.V. - Common Shares  (ATAI) 
US:NASDAQ Investor Relations: ir.atai.net.cn
PDF - A single dose of BPL-003 demonstrated a rapid and durable antidepressant effect in TRD patients, with 45% of patients in clinical remission at week 12 - 55% of patien [Read more]